Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REJOIN: Extension Study of Eptinezumab in Children and Adolescents With Migraine
NCT05164172Phase 3Recruiting
- Sponsor
- Lundbeck
- Start
- Dec 2021
- Primary completion
- Apr 2028
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 11
01
Overview
Phase 3, randomised, open-label trial of eptinezumab in migraine, sponsored by Lundbeck. Primary endpoint: Treatment Emergent Adverse Events. Started Dec 2021; status: recruiting.
02
Drugs
eptinezumab
03
Conditions
migraine
Beyond the preview
Go deeper on NCT05164172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05164172.